Central laboratory analysis of the recurrent breast cancer demonstrated that the ER staining was positive in 101 (73.7%), PR was positive in 75 (54.7%), and HER2 was positive in 16 subjects (11.7%). This evidence concerns the gene ERBB2 and breast carcinoma.